Summit Therapeutics (SMMT) Has Tumbled To A New Low After Study Failed

Summit Therapeutics (SMMT) announced Wednesday morning that its Phase 2 study of ezutromid failed to meet its primary or secondary endpoints.

Summit Therapeutics gapped open sharply lower this morning and is now down 10.35 at $2.29 on strong volume. The stock has tumbled to a new low for the year.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Biotech Stocks by Subscribing to RTT Biotech Investor.
Follow RTT